These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34491986)

  • 1. Episome partitioning and symmetric cell divisions: Quantifying the role of random events in the persistence of HPV infections.
    Beneteau T; Selinger C; Sofonea MT; Alizon S
    PLoS Comput Biol; 2021 Sep; 17(9):e1009352. PubMed ID: 34491986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HPV clearance and the neglected role of stochasticity.
    Ryser MD; Myers ER; Durrett R
    PLoS Comput Biol; 2015 Mar; 11(3):e1004113. PubMed ID: 25769112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Host defence and persistent human papillomavirus infection.
    Stanley M
    Curr Opin Virol; 2021 Dec; 51():106-110. PubMed ID: 34628358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of inflammation in HPV carcinogenesis.
    Boccardo E; Lepique AP; Villa LL
    Carcinogenesis; 2010 Nov; 31(11):1905-12. PubMed ID: 20819779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biology and pathological associations of the human papillomaviruses: a review.
    Cheah PL; Looi LM
    Malays J Pathol; 1998 Jun; 20(1):1-10. PubMed ID: 10879257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evasion of host immune defenses by human papillomavirus.
    Westrich JA; Warren CJ; Pyeon D
    Virus Res; 2017 Mar; 231():21-33. PubMed ID: 27890631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer.
    Sasagawa T; Takagi H; Makinoda S
    J Infect Chemother; 2012 Dec; 18(6):807-15. PubMed ID: 23117294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring individual HPV coinfections is essential to predict HPV-vaccination impact on genotype distribution: a model-based approach.
    Pons-Salort M; Letort V; Favre M; Heard I; Dervaux B; Opatowski L; Guillemot D
    Vaccine; 2013 Feb; 31(8):1238-45. PubMed ID: 23246257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in preclinical model systems for papillomaviruses.
    Christensen ND; Budgeon LR; Cladel NM; Hu J
    Virus Res; 2017 Mar; 231():108-118. PubMed ID: 27956145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Animal models of papillomavirus pathogenesis.
    Campo MS
    Virus Res; 2002 Nov; 89(2):249-61. PubMed ID: 12445664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discrete-time semi-Markov modeling of human papillomavirus persistence.
    Mitchell CE; Hudgens MG; King CC; Cu-Uvin S; Lo Y; Rompalo A; Sobel J; Smith JS
    Stat Med; 2011 Jul; 30(17):2160-70. PubMed ID: 21538985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of human papillomavirus infection: keys to malignant progression.
    Bodily J; Laimins LA
    Trends Microbiol; 2011 Jan; 19(1):33-9. PubMed ID: 21050765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of human papillomaviruses and current vaccine strategies.
    Gnanamony M; Peedicayil A; Abraham P
    Indian J Med Microbiol; 2007 Jan; 25(1):10-7. PubMed ID: 17377346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial cell responses to infection with human papillomavirus.
    Stanley MA
    Clin Microbiol Rev; 2012 Apr; 25(2):215-22. PubMed ID: 22491770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunity to oncogenic human papillomaviruses.
    Konya J; Dillner J
    Adv Cancer Res; 2001; 82():205-38. PubMed ID: 11447764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into the Role of Innate Immunity in Cervicovaginal Papillomavirus Infection from Studies Using Gene-Deficient Mice.
    Scagnolari C; Cannella F; Pierangeli A; Mellinger Pilgrim R; Antonelli G; Rowley D; Wong M; Best S; Xing D; Roden RBS; Viscidi R
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32295905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence, clearance and reinfection regarding six high risk human papillomavirus types in Colombian women: a follow-up study.
    Soto-De León SC; Del Río-Ospina L; Camargo M; Sánchez R; Moreno-Pérez DA; Pérez-Prados A; Patarroyo ME; Patarroyo MA
    BMC Infect Dis; 2014 Jul; 14():395. PubMed ID: 25030273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of interferon signaling in human papillomavirus infection.
    Koromilas AE; Li S; Matlashewski G
    Cytokine Growth Factor Rev; 2001; 12(2-3):157-70. PubMed ID: 11325599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of apoptotic pathways by human papillomaviruses (HPV): mechanisms and implications for therapy.
    Yuan CH; Filippova M; Duerksen-Hughes P
    Viruses; 2012 Dec; 4(12):3831-50. PubMed ID: 23250450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV-induced oropharyngeal cancer, immune response and response to therapy.
    Vu HL; Sikora AG; Fu S; Kao J
    Cancer Lett; 2010 Feb; 288(2):149-55. PubMed ID: 19628331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.